Familial hypercholesterolaemia: identification and management
KEYWORDS: people, healthcare, disease, therapy, coronary, healthcare professionals, professionals, children, heart disease, coronary heart, heart, concentration, risk, ldl-c, drug

should offer adults with FH a referral to a specialist with expertise in FH for consideration for further treatment if they are assessed to be at very high risk of a coronary event, that is, if they have any of the following. • Established coronary heart disease. • A family history of premature coronary heart disease. • Two or more other cardiovascular risk factors (for example, they are male, they smoke, or they have hypertension or diabetes). [2008] 1.3.1.13 For recommendations on managing primary heterozygous familial hypercholesterolaemia in people whose LDL-C levels are not adequately controlled despite maximal tolerated lipid-lowering therapy, see the NICE technology appraisal guidance on alirocumab and evolocumab. [2017] 1.3.1.14 Adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin) or a fibrate to reduce their LDL-C concentration. [2008, amended 2017] 1.3.1.15 The decision to offer treatment with a bile acid sequestrant (resin) or a fibrate in addition to initial statin therapy should be taken by a specialist with expertise in FH. [2008, amended 2017] 1.3.1.16 Healthcare professionals should exercise caution when adding
